Invasive Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature

J Mycol Med. 2022 May;32(2):101236. doi: 10.1016/j.mycmed.2021.101236. Epub 2021 Dec 23.

Abstract

Candida kefyr (Kluyveromyces marxianus), an ascomycetous environmental yeast, occasionally isolated from dairy products, represents an uncommon but emerging pathogen in immunocompromised patients. Herein, we present a case of C. kefyr pyelonephritis in a 41-year-old, previously immunocompetent, patient who was hospitalized in an COVID-19 ICU. Pyelonephritis was associated with caliectasis and obstruction due to possible fungus ball formation. Predisposing factors included ICU stay, use of broad spectrum antibiotics and steroids, central venous catheterization, mechanical ventilation and urologic manipulation. Susceptibility testing revealed high MIC values to amphotericin B. Infection was effectively controlled by prolonged administration of fluconazole without further surgical intervention. COVID-19 complicated with invasive candidiasis is an increasingly observed clinical situation that warrants high suspicion index and careful evaluation of laboratory data.

Keywords: COVID-19; Candida kefyr; ICU; Invasive candidiasis; Pyelonephritis; Urinary tract infection.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use
  • COVID-19* / complications
  • Candida
  • Candidiasis
  • Candidiasis, Invasive* / diagnosis
  • Candidiasis, Invasive* / drug therapy
  • Fluconazole / therapeutic use
  • Humans
  • Intensive Care Units
  • Kluyveromyces
  • Pyelonephritis* / diagnosis
  • Pyelonephritis* / drug therapy

Substances

  • Antifungal Agents
  • Fluconazole

Supplementary concepts

  • Kluyveromyces marxianus
  • Systemic candidiasis